Autifony appoints John Hutchison as chief medical officer

3 September 2015

Autifony Therapeutics, a UK-based biotech company specializing in hearing loss and tinnitus, has appointed John Hutchison as chief medical officer.

Dr Hutchison joined the company in 2012 from Pfizer (NYSE: PFE), where he was chief medical officer and vice president of clinical research for Pfizer Neusentis in the UK. He will head Autifony’s clinical development team that will oversee the evaluation of two candidate drugs in multiple clinical trials by the end of the year.

Charles Large, chief executive of Autifony Therapeutics, commented: “Dr Hutchison brings new experience and insights that will help us to realize the full potential of our Kv3 ion channel platform. Our exciting new clinical development program for schizophrenia will enter Phase I later this year, and John’s CNS experience will be critical to our ambitions. These ambitions go beyond schizophrenia to include other CNS indications of high unmet medical need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK